Загрузка...
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
Current non-small cell lung cancer (NSCLC) chemotherapy and radiotherapy regimens, although showing definite survival benefit, still leave patients with a disappointing 15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research has focused on identifying specific...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2990321/ https://ncbi.nlm.nih.gov/pubmed/21116327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S8617 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|